Get the Stockscreener App
4.92
2.71%
0.13
Pre-market:
4.91
-0.010
-0.20%
Ardelyx Inc stock is traded at $4.92, with a volume of 4.31M.
It is up +2.71% in the last 24 hours and down -15.75% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$4.79
Open:
$4.75
24h Volume:
4.31M
Relative Volume:
1.17
Market Cap:
$1.17B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-41.00
EPS:
-0.12
Net Cash Flow:
$-63.80M
1W Performance:
+9.33%
1M Performance:
-15.75%
6M Performance:
-37.96%
1Y Performance:
+12.33%
1-Day Range:
$4.68
$4.96
1-Week Range:
$4.43
$5.06
52-Week Range:
$4.06
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ARDX | 4.92 | 1.17B | 251.85M | -72.58M | -63.80M | -0.12 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Ardelyx Executives to Present at Piper Sandler Healthcare Conference | ARDX Stock News - StockTitan
Jefferies optimistic on Ardelyx stock as management navigates reimbursement changes - Investing.com
US Penny Stocks To Monitor In November 2024 - Simply Wall St
Ardelyx, Inc. (NASDAQ:ARDX) Short Interest Up 5.1% in October - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Gap UpTime to Buy? - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Ardelyx Inc H - GuruFocus.com
Director David Mott Acquires 215,868 Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability (NASDAQ:ARDX) - Seeking Alpha
HC Wainwright Has Bearish Forecast for Ardelyx Q1 Earnings - MarketBeat
Ardelyx (NASDAQ:ARDX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Ardelyx shares downgraded amid sales concerns for XPHOZAH By Investing.com - Investing.com Australia
Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop - Seeking Alpha
Ardelyx (NASDAQ:ARDX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Ardelyx shares downgraded amid sales concerns for XPHOZAH - Investing.com India
Ardelyx (NASDAQ:ARDX) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Ardelyx chief development officer sells shares worth $165,743 - Investing.com India
Ardelyx chief development officer sells shares worth $165,743 By Investing.com - Investing.com Australia
David P. Rosenbaum Sells 27,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock - MarketBeat
Ardelyx Beats Q3 Sales Estimates, Shares Climb - MSN
Ardelyx Loses Bid to Block HHS Classification of Kidney Drug - Bloomberg Law
Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update) - MSN
Ardelyx Responds to District Court Decision Granting Motion to Dismiss - The Manila Times
Ardelyx (NASDAQ:ARDX) Shares Gap DownTime to Sell? - MarketBeat
Ardelyx ‘disappointed’ by court decision granting motion to dismiss - TipRanks
Ardelyx Stock Alert: Court Dismisses CMS Lawsuit, XPHOZAH Access Concerns Mount | ARDX Stock News - StockTitan
Ardelyx falls after court dismisses lawsuit against CMS over company's kidney disease drug - XM
Ardelyx chief development officer sells $161,673 in stock - Investing.com
Ardelyx chief development officer sells $161,673 in stock By Investing.com - Investing.com Canada
(ARDX) Investment Analysis - Stock Traders Daily
Citigroup Lowers Ardelyx (NASDAQ:ARDX) Price Target to $10.00 - Defense World
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference - ForexTV.com
Ardelyx (ARDX) Leadership to Present at Jefferies London Healthcare Conference 2024 | ARDX Stock News - StockTitan
What is Wedbush’s Forecast for Ardelyx FY2026 Earnings? - Defense World
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Inve - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Price Target Lowered to $10.00 at Citigroup - MarketBeat
Wedbush Has Negative Outlook for Ardelyx FY2026 Earnings - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Call Transcript - MSN
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Ardelyx (NASDAQ:ARDX) Stock Price Up 7.3% – Here’s Why - Defense World
Allspring Global Investments Holdings LLC Sells 19,212 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seekin - GuruFocus.com
Ardelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) - Yahoo Finance
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics - MSN
Ardelyx (NASDAQ:ARDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Earnings call: Ardelyx reports solid growth amid Medicare challenges - Investing.com
Earnings call: Ardelyx reports solid growth amid Medicare challenges By Investing.com - Investing.com Canada
Ardelyx (NASDAQ:ARDX) Shares Up 7.3%Should You Buy? - MarketBeat
Ardelyx Target of Unusually High Options Trading (NASDAQ:ARDX) - MarketBeat
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):